Literature DB >> 16037946

Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.

Sachin S Kunde1, Audrey J Lazenby, Ronald H Clements, Gary A Abrams.   

Abstract

The upper limit of normal for ALT activity has been recommended to be lowered to < or = 30 U/L in men and < or = 19 U/L in women. These changes have been suggested to be diagnostically useful in subjects with nonalcoholic fatty liver disease (NAFLD). Our aim was to investigate the prevalence and spectrum of NAFLD with regard to the new ALT guidelines in 233 women with class II/III obesity. We compared our prior reference range for ALT (ULN < or = 30 U/L in women) with the new standard. Our study demonstrates that only 86 patients (36.9%) would be classified as having normal ALT levels compared with 169 patients (72.5%) by the new and old standards, respectively. In patients with normal ALT activity (new vs. old standard), the prevalence of fatty liver (FL: 39.5% vs 40.2%), portal fibrosis, and steatosis (IPF: 37.2% vs. 33.7%) and nonalcoholic steatohepatitis (NASH: 23.3% vs. 26%) were similar. In comparison, newly defined patients with elevated ALT levels (>19 U/L) demonstrated an increased prevalence of FL (36%) and IPF (11.6%) but a 23.8% decrease in the prevalence of NASH as compared with the old standard. The sensitivity and specificity for NASH were 42% and 80% (ALT > 30 U/L) compared with 74% and 42% (ALT > 19 U/L). In conclusion, a significant increase in the prevalence of FL and IPF is detected in subjects with elevated ALT levels with the application of the new standard. However, the diagnostic utility for ALT to identify NASH or IPF remains poor, and significant healthcare expenditures may be incurred if this standard is adopted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037946     DOI: 10.1002/hep.20818

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  67 in total

1.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

Review 2.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

3.  The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Yoshio Sumida; Eriko Ishibashi; Yoichiro Kitajima; Hiroshi Isoda; Hiroko Horie; Takaya Tashiro; Eri Iwamoto; Hirokazu Takahashi; Takuya Kuwashiro; Shu Soejima; Yasunori Kawaguchi; Yasutomo Oda; Sei Emura; Ryuichi Iwakiri; Iwata Ozaki; Takahisa Eguchi; Naofumi Ono; Keizo Anzai; Kazuma Fujimoto; Shunzo Koizumi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

4.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels.

Authors:  Brent A Neuschwander-Tetri; Aynur Unalp; Michael H Creer
Journal:  Arch Intern Med       Date:  2008-03-24

Review 5.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

6.  Is there any progress in the treatment of non-alcoholic fatty liver disease?

Authors:  Emmanuel A Tsochatzis; George V Papatheodoridis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

Review 7.  Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.

Authors:  Lauren Pavlik; Arie Regev; Paul A Ardayfio; Naga P Chalasani
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

Review 8.  Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Authors:  Howard P Monsour; Catherine T Frenette; Kathleen Wyne
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

9.  Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease.

Authors:  Diana R Mager; Simon Ling; Eve A Roberts
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

10.  Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?

Authors:  Giovanni Tarantino; Paolo Conca; Antonio Riccio; Marianna Tarantino; Matteo N Di Minno; Domenico Chianese; Fabrizio Pasanisi; Franco Contaldo; Francesco Scopacasa; Domenico Capone
Journal:  J Transl Med       Date:  2008-11-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.